Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer

Zachary A P Wintrob, Jeffrey P. Hammel, George K. Nimako, Dan P. Gaile, Alan Forrest, Alice C. Ceacareanu

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

Oral drugs stimulating insulin production may impact growth factor levels. The data presented shows the relationship between pre-existing insulin secretagogues use, growth factor profiles at the time of breast cancer diagnosis and subsequent cancer outcomes in women diagnosed with breast cancer and type 2 diabetes mellitus. A Pearson correlation analysis evaluating the relationship between growth factors stratified by diabetes pharmacotherapy and controls is also provided.

LanguageEnglish (US)
Pages459-468
Number of pages10
JournalData in Brief
Volume11
DOIs
StatePublished - Apr 1 2017

Fingerprint

incident
cancer
chronic illness
drug
time

Keywords

  • Breast cancer
  • Cancer outcomes
  • Cancer prognosis
  • Diabetes
  • EGF
  • FGF
  • Growth factor
  • HGF
  • Insulin secretagogue
  • PDGF
  • TGF
  • VEGF

ASJC Scopus subject areas

  • Education
  • General

Cite this

Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer. / Wintrob, Zachary A P; Hammel, Jeffrey P.; Nimako, George K.; Gaile, Dan P.; Forrest, Alan; Ceacareanu, Alice C.

In: Data in Brief, Vol. 11, 01.04.2017, p. 459-468.

Research output: Contribution to journalArticle

Wintrob, Zachary A P ; Hammel, Jeffrey P. ; Nimako, George K. ; Gaile, Dan P. ; Forrest, Alan ; Ceacareanu, Alice C. / Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer. In: Data in Brief. 2017 ; Vol. 11. pp. 459-468.
@article{3f024b97ba7b430f84361cb8a4c4e26c,
title = "Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer",
abstract = "Oral drugs stimulating insulin production may impact growth factor levels. The data presented shows the relationship between pre-existing insulin secretagogues use, growth factor profiles at the time of breast cancer diagnosis and subsequent cancer outcomes in women diagnosed with breast cancer and type 2 diabetes mellitus. A Pearson correlation analysis evaluating the relationship between growth factors stratified by diabetes pharmacotherapy and controls is also provided.",
keywords = "Breast cancer, Cancer outcomes, Cancer prognosis, Diabetes, EGF, FGF, Growth factor, HGF, Insulin secretagogue, PDGF, TGF, VEGF",
author = "Wintrob, {Zachary A P} and Hammel, {Jeffrey P.} and Nimako, {George K.} and Gaile, {Dan P.} and Alan Forrest and Ceacareanu, {Alice C.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.dib.2017.02.038",
language = "English (US)",
volume = "11",
pages = "459--468",
journal = "Data in Brief",
issn = "2352-3409",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer

AU - Wintrob, Zachary A P

AU - Hammel, Jeffrey P.

AU - Nimako, George K.

AU - Gaile, Dan P.

AU - Forrest, Alan

AU - Ceacareanu, Alice C.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Oral drugs stimulating insulin production may impact growth factor levels. The data presented shows the relationship between pre-existing insulin secretagogues use, growth factor profiles at the time of breast cancer diagnosis and subsequent cancer outcomes in women diagnosed with breast cancer and type 2 diabetes mellitus. A Pearson correlation analysis evaluating the relationship between growth factors stratified by diabetes pharmacotherapy and controls is also provided.

AB - Oral drugs stimulating insulin production may impact growth factor levels. The data presented shows the relationship between pre-existing insulin secretagogues use, growth factor profiles at the time of breast cancer diagnosis and subsequent cancer outcomes in women diagnosed with breast cancer and type 2 diabetes mellitus. A Pearson correlation analysis evaluating the relationship between growth factors stratified by diabetes pharmacotherapy and controls is also provided.

KW - Breast cancer

KW - Cancer outcomes

KW - Cancer prognosis

KW - Diabetes

KW - EGF

KW - FGF

KW - Growth factor

KW - HGF

KW - Insulin secretagogue

KW - PDGF

KW - TGF

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85014361778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014361778&partnerID=8YFLogxK

U2 - 10.1016/j.dib.2017.02.038

DO - 10.1016/j.dib.2017.02.038

M3 - Article

VL - 11

SP - 459

EP - 468

JO - Data in Brief

T2 - Data in Brief

JF - Data in Brief

SN - 2352-3409

ER -